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Abstract: Recent data have indicated a fundamental role of iron in mediating a non-apoptotic and
non-necrotic oxidative form of programmed cell death termed ferroptosis that requires abundant
cytosolic free labile iron to promote membrane lipid peroxidation. Different scavenger molecules
and detoxifying enzymes, such as glutathione (GSH) and glutathione peroxidase 4 (GPX4), have
been shown to overwhelm or exacerbate ferroptosis depending on their expression magnitude.
Ferroptosis is emerging as a potential weapon against tumor growth since it has been shown to
potentiate cell death in some malignancies. However, this mechanism has been poorly studied in
Rhabdomyosarcoma (RMS), a myogenic tumor affecting childhood and adolescence. One of the
main drivers of RMS genesis is the Retrovirus Associated DNA Sequences/Extracellular signal
Regulated Kinases (RAS/ERK)signaling pathway, the deliberate activation of which correlates with
tumor aggressiveness and oxidative stress levels. Since recent studies have indicated that treatment
with oxidative inducers can significantly halt RMS tumor progression, in this review we covered
different aspects, ranging from iron metabolism in carcinogenesis and tumor growth, to mechanisms
of iron-mediated cell death, to highlight the potential role of ferroptosis in counteracting RMS growth.
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1. Introduction
Iron is the most abundant heavy metal in mammals (about 3–5 g in human adults), as it is
involved in a number of biological processes, ranging from metabolism and oxygen transport to DNA
synthesis and antioxidant defense. Many redox enzymes involved in cellular respiration use iron-sulfur
(Fe-S) clusters as preferred cofactors, named ferredoxins, such as nicotinamide adenine dinucleotide
(NADH) dehydrogenase, hydrogenases, coenzyme Q—cytochrome c reductase, succinate-coenzyme Q
reductase and other components of the mitochondrial electron transport chain. In addition, heme iron is
used for oxygen transport by hemoglobin and myoglobin and for the detoxification of reactive oxygen
species (ROS) by catalase and superoxide dismutase enzymes. Often tumor cells show a marked
alteration in metabolism leading to intracellular accumulation of iron, which is strongly utilized for
tumor growth and angiogenesis [1]. Accordingly, some anti-tumor strategies using metal chelators
have been successfully developed [2]; however, iron deprivation is potentially harmful to non-tumor
cells, as it may favor cell death by apoptosis [3–5]. Recently, an iron-dependent type of programmed
cell death has been identified, named ferroptosis [6–8]. High intracellular iron concentrations can
trigger ferroptosis by enhancing the generation of lipid peroxides, and this can be reverted using iron
chelators [9]. Currently, the use of ferroptosis as a weapon against tumors is of increasing interest,
as tumor cells traditionally exhibit high endogenous oxidative stress levels due to gene aberrations
promoting continuous cell cycles (gain of RAS, and myelocytomatosis viral related oncogene MYC)
and resistance to cell senescence (P53 loss) [10]. In the next paragraphs we will describe the complex
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role of iron in cancer and discuss the available evidence on iron and ferroptosis in rhabdomyosarcoma
(RMS), the most frequent soft tissue tumor affecting patients of pediatric and adolescent age.
2. The Pleiotropic Role of Iron in Cancer
Deregulation of iron homeostasis may have a different impact in cancer depending on the stage of
tumor progression, as summarized in Figure 1. As detailed below, iron levels influence carcinogenesis,
tumor progression and sensitivity to ferroptosis.
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carcinogenesis [13]. In particular, the most frequent DNA damage is the 
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG), resulting from the oxidation of guanine, which 
potently induces G:C→T:A transversion mutations. Several enzymes involved in DNA repair have 
been identified, such as the 8-oxoguanine DNA glycosylase 1 (OGG1) [14,15] and a homologue MutT 
variant first isolated in a mutant strain of E. coli [16]. Interestingly, patients with chronic hepatitis C, 
who have abnormally high levels of 8-oxo-dG and repair enzymes, are protected from the formation 
of pre-neoplastic lesions and hepatocellular carcinoma by phlebotomy and a low iron diet [17,18]. 
Other studies further confirmed that phlebotomy twice a year for five years significantly protects 
against cancer events [19]. Altogether these data indicate that iron-induced oxidative stress can 
represent a critical factor for carcinogenesis induced by DNA mutagenesis [20–22]. 
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all tissues presenting the transferrin receptor 1 (TfR1), which mediates its endocytosis [23]. Iron is
then reduced and delivered throughout the cytosol to mitochondria for the synthesis of heme groups,
Fe/S complexes and iron enzymes, whereas the excess is sequestered and stored by ferritins [26]
(Figure 2). The amount of iron bound to ferritins (up to 4500 atoms) can be recycled via a recently
identified mechanism mediated by a nuclear receptor coactivator 4 (NCOA4), which targets H-ferritin
to lysosomal degradation [27]. As a result of these coordinated events, in non-tumor cells only a minor
fraction of free labile iron is present in the cytosol, usually complexed with low molecular weight
molecules including glutathione (GSH), citrate, sugars, ascorbate, nucleotides, and also enzymes [23].
On the other hand, an abnormal increase of the intracellular free iron pool is observed in cancer cells,
as described in ovarian, breast, lung, prostate, and pancreatic tumors, colorectal hepatoma, gastric and
hematological cancers, and melanoma [1]. This effect, commonly referred as to “iron addiction” [1], is
the result of the deregulation of different mechanisms. For example, altered MYC expression, which
plays a key role in cell transformation, is also responsible for iron metabolism by modulating the
activity of the iron responsive protein-2 (IRP2), which in turn orchestrates the expression of different
iron proteins [28]. As depicted in Figure 2, cancer cells show increased iron absorption due to high
expression of TfR1, a downstream target of MYC oncoprotein [29] and hypoxia inducible factors
(HIFs) [30], as observed in breast, renal, and ovarian tumors [31–33]. In addition, the down-regulation
of FPN mediated by hepcidin can limit iron export [34], whereas MYC and RAS can promote the
release of stored iron by the degradation of H-ferritin [35,36]. Finally, the stroma, endothelial and
inflammatory cells composing the tumor niche can release iron to feed the neighboring tumor cells
through a concerted upregulation of FPN and down-regulation of ferritin and heme-oxygenase [37].
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down-regulation of FPN mediated by secreted hepcidin and lower levels of ferritins, which leads to 
an increased intracellular labile iron pool; despite this it’s mostly being utilized for tumor growth by 
cytosolic and mitochondrial iron enzymes, the exceeding amount can promote increased oxidative 
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website (available online: www.servier.com) licensed under the creative commons attribution 3.0 
unported license (available online: http://creativecommons.org/license/by/3.0/). 
Iron a diction of tumor cells. In normal cells the transfer in receptor 1 (TfR1)-mediated
iron abs rption is counter balanced by iron efflux via ferroportin (FPN); the free iron pool i used
b cytosolic and mit chondrial enzymes and the xces is stored by ferritins to preven cytotoxicity.
As a result, only a minor part of the intracellular iron, present as a free abile pool, can stimulat
the formation of Reactive Oxygen Species ROS. In contrast, tumor cells often show high r levels of
TfR1, down-regulation of FPN mediated by secrete hepcidin and lower levels of ferritins, which
leads to an incre s d intracel ular labile iron pool; despite this it’s mostly b ing utilized for tumor
growth by cytosoli and mitochondrial iron enzym s, the exceeding amount can promote incre sed
oxidati e stress via ROS ccumulation. The figure was adapted using a template on the s vier medical
art website (available o line: ww.servier.com) licensed under the creative co ons tt i ti .
rt lic s ( il l li : tt : /creativecommons.org/license/by/3.0/).
Int. J. Mol. Sci. 2017, 18, 1718 4 of 13
2.3. Iron as a Trigger of Ferroptosis in Tumor Cells
Ferroptosis is an iron-dependent form of programmed cell death [6] that differs from canonical
apoptosis, necroptosis or autophagy in its morphological features and biochemical pathways [38–40]. As
depicted in Figure 3, intracellular iron accumulation yields hydroxyl radicals via the Fenton reaction,
therefore promoting the oxidation of polyunsaturated fatty acids (PUFAs, such as linoleic, arachidonic
and docosahexaenoic acids). The resulting lipid peroxides and hydroperoxides [41] cause severe
structural/functional alterations of cell membranes [8]. Treatments with iron chelators, antioxidant
scavengers (like GSH or Vitamin E), and specific inhibitors of lipid peroxidation (like Ferrostatin-1) can
prevent ferroptosis activation [6,42]. Moreover, glutathione peroxidase 4 (GPX4), a selenoprotein, protects
from ferroptosis [43] as it catalyzes the endogenous neutralization of lipid hydroperoxides (L-OOH) into
innocuous lipid alcohols [44,45]. Indeed, the treatment of cells with the GPX4 inhibitor RSL3 (RAS selective
lethal 3) rapidly induces ferroptosis [43]. On the other hand, erastin (eradicator of RAS and ST-expressing
cells) facilitates ferroptosis preferentially in RAS-positive cancer cells [46,47]. Preliminary studies have
shown that erastin inhibits the membrane potential of mitochondria [48], while subsequent studies
have elucidated how erastin reduces GPX4 activity [6]. Specifically erastin, similarly to sulfasalazine [6],
sorafenib [49,50] and glutamate [6], inhibits cystine absorption from the extracellular space mediated
by system Xc−, a glutamate-cystine antiporter [6,51]; this reduces the intracellular biosynthesis of GSH,
leading to subsequent impairment of GPX4 activity. After its recent discovery in 2012, the importance of
ferroptosis has attracted much interest as it represents a potential mechanism for controlling tumor growth.
To date, different types of tumor have shown sensitivity to ferroptosis inducers [10], including diffuse
large B-cell lymphoma, renal cell carcinoma, liver cancer, cervical carcinoma, osteosarcoma, prostate
adenocarcinoma, pancreatic carcinoma, and ovarian carcinoma [43,52–54]. In addition, several proteins
and pathways have been described as modulators of ferroptosis (Table 1). However, few studies have so
far documented the ferroptosis process in sarcomas.
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Figure 3. Intracellular levels of iron, glutathione (GSH) and polyunsaturated fatty acids (PUFAs)
influence ferroptosis. The abundant intracellular iron through the Fenton reaction can result in higher
formation of hydroxyl radicals (•OH), the most reactive ROS (Reactive Oxygen Species) intermediates.
These pr m te conversi n of PUFAs into lipid hydroper xides (L–OOH) that lead t ferroptosis. This
process can be exacerbated pharmacologically by the inhibition of glutathione peroxidase 4 (GPX4),
the enzyme responsible for L–OOH neutralization, by treatme t with RAS s lective lethal 3 (RSL3).
Alternatively, GPX4 activity may be inhibited by a depletion of GSH via treatment with inhibitors of
the system Xc− responsible for cystine uptake (such as erastin, sorafenib, glutamate and sulfasalazine)
or with buthionine-sulfoximine (BSO), an inhibitor of the first reaction of GSH biosynthesis. The
system Xc− is also transcriptionally repressed by p53. In addition, treatment with inhibitors of the
mevalonate pathway, such as statins, affect GPX4 synthesis and stimulate ferroptosis. On the other
hand, strategies to prevent ferroptosis include treatment with iron chelators such as deferoxamine
(DFO) and neutralization of L-OOH by treatment with lipid peroxidation inhibitors (Ferrostatin-1) and
antioxidant scavengers (GSH, Vitamin E).
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Table 1. Proteins and pathways modulating ferroptosis.
Pro-Ferroptosis Function References
ACSL4 Acyl-CoA synthase long-chain 4 increases the fraction of long polyunsaturatedω6 fatty acids incellular membranes [55]
CARS Cysteinyl-tRNA synthetase is an enzyme involved in charging of tRNAs with cysteine forprotein translation [56]
Gln Glutamine via glutaminolysis is essential for ferroptosis triggered by deprivation of full aminoacids or of cystine alone [57]
HO-1 Heme oxygenase-1 is a heme-degrading enzyme releasing iron [58]
LOX-5 Lipoxygenase-5 catalyzes the dioxygenation of PUFAs [8]
NCOA4 Nuclear receptor coactivator 4 promotes H-Ferritin degradation [27,59]
NOX NADPH oxidase produces ROS species [6]
P53 It represses the expression of SLC7A11 encoding a subunit of the system Xc− [60]
SAT1 Spermidine/spermine N-acetyltransferase increases the peroxidation of arachidonic acid [61]
TfR1 Transferrin receptor 1 is involved in the iron uptake [57]
Anti-Ferroptosis Function References
Ferritin The main intracellular iron storage protein [62]
GPX4 Glutathione peroxidase-4 is a selenoenzyme neutralizing lipid hydroperoxides [43]
HSPA5 Heath shock protein-5 prevents GPX4 degradation [63]
HSPB1 Heat shock protein β-1 protects from lipid ROS [52]
IRP2 Iron responsive protein-2 controls the transcription of TfR1, Ferritin and FPN [62]
MT-1 Metallothionein-1 binds heavy metals [64,65]
Mevalonate pathway Pathway controlling the biosynthesis of selenoproteins, such as GPX4 [66]
Mitochondrial Ferritin Iron-storage protein [67]
NRF2 Nuclear factor erythroid 2-related factor 2 drives a transcriptional antioxidant program [68]
System Xc− The antiporter involved in cystine absorption [60]
3. Ferroptosis and Rhabdomyosarcoma
3.1. Rhabdomyosarcoma Is a Soft Tissue Sarcoma Characterized by Oxidative Stress
Sarcomas are mesenchymal tumors originating from cell precursors committed to form fat, blood
vessels, nerves, bones, muscles, deep skin tissues, and cartilage. The latest classification by the World
Health Organization [69] divided sarcomas into non-soft tissue sarcomas and soft-tissue sarcomas (STS).
The former includes bone sarcomas such as osteosarcoma, Ewing’s sarcoma, and chondrosarcoma;
while the latter includes a family of more than 50 neoplasms representing about 20% of childhood
and adolescence tumors and 1% of all adult cancers. RMS arises from cell progenitors committed to
skeletal muscle [70–73] and is the most common STS in patients of pediatric and adolescent age [74,75].
RMS subdivides into four main subtypes depending on histology appearance, tumor location, age of
onset, and molecular drivers (Table 2).
Table 2. Histological classification and molecular drivers of rhabdomyosarcom (RMS).
RMS Histotypes % of AllRMS Cases Location Age Prognosis Dominant Molecular Drivers
Embryonal 60%
Genitourinary tract, head and
neck, urinary bladder, prostate,
biliary tract, abdomen, pelvis,
retroperitoneum
<10 favorable
Activating mutations in PDGFRA,
ERBB2, FGFR4, RAS,
PIK3CA [76–79]
IGF-2 overexpression [80,81]
Somatic mutations in p53 [82]
Alveolar 20%
Extremities, head and neck,
chest, genital organs, abdomen
and anal area
10–20 unfavorable
Chromosomal translocation
t(2;13)(q35;q14) [83,84]
N-MYC overexpression [85]
IGF-2 overexpression [81]
Pleomorphic 10% Extremities, chest and abdomen 60–80 unfavorable Complex karyotypes with norecurrent structural alterations
Spindle cell 10% Paratesticular, head and neck <10 and>40
favorable (children)
unfavorable (adults)
NCOA2 gene rearrangements [86]
Mutations in MYOD1 [87]
Abbreviations used are: ERBB2, erb-b2 receptor tyrosine kinase 2; FGFR4, fibroblast growth factor receptor 4;
IGF-2, insulin-like growth factor 2; MYOD1, myogenic differentiation 1; NCOA2, Nuclear Receptor Coactivator 2;
MYC, myelocytomatosis viral related oncogene; PDGFRA, platelet-derived growth factor receptor A; PIK3CA,
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; RAS, retrovirus-associated DNA sequences.
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The two predominant histotypes are the embryonal (ERMS) and the alveolar (ARMS) forms that
commonly affect children under 10 years or adolescents/young adults, respectively [88]. Currently,
chemotherapy, radiotherapy, and surgery are used to treat this aggressive tumor, with a five-year
survival rate of higher than 70% in patients with localized disease; however, the overall survival of
patients with metastasis remains low [89,90]. Different types of molecular drivers have been identified
for each RMS subtype (Table 2) [91]. The most aggressive ARMS is dominated by a chromosomal
translocation t(2;13)(q35;q14) that juxtaposes the DNA binding domain of the PAX3 gene in a frame
with the activation domain of the FOXO1 gene, giving rise to a Pax3-Foxo1 chimeric transcription factor
that is found in 70% of ARMS cases and is considered a predictor of poor prognosis [92,93]. ERMS is the
most frequent form and is characterized by activating mutations in a number of receptor and transducer
molecules, which cause the deliberate activation of the extracellular regulated kinases 1/2 (ERK1/2)
and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling pathways [69,71]. Among the
oncogenic transducers, RAS is considered a major driver of ERMS etiogenesis [94], as the RASG12V
mutated form is sufficient to convert normal myogenic cell precursors into pre-neoplastic and neoplastic
counterparts [82,95]. Accordingly, germline RAS mutations on chromosome 11p15.5 are causative of
the Costello syndrome, which predisposes individuals to the formation of embryonic tumors, including
ERMS [96]. Sustained RAS activation correlates with ERMS tumor risk and was shown to promote
a higher rate of G→T transversions due to high ROS formation [97,98]. As a consequence, RMS tumors
were reported to be sensitive to a number of oxidative inducers [97], including auranofin—an inhibitor
of thioredoxin reductase [99], cervistatin—a synthetic statin causing mitochondrial impairment [100],
and ouabain—a glycoside inhibiting the Na+/K+ ATPase activity (Table 3). According to these findings,
the identification of oxidative-stress inducers represents a milestone for the implementation of the
therapeutic regimen of RMS.
Table 3. Oxidative stress inducers that have shown efficacy in RMS treatment.
Agents Targets Reference
auranofin Inhibitor of thioredoxin reductase [97]
buthionine-sulfoximine Inhibitor of the first step of GSH biosynthesis [101]
cervistatin Synthetic statin causing mitochondrial impairment [97]
NBDHEX Inhibitor of GSH transferase P1-1 [102]
ouabain Inhibitor of the Na+/K+ ATPase activity [97]
sorafenib Inhibitor of system Xc− [103]
3.2. Ferroptosis in Rhabdomyosarcoma: State of the Art
Schott et al. found that lentiviral infection of mutated hyperactive RAS forms (NRASG12V,
KRASG12V and HRASG12V) in the RMS13 cell line significantly protected against ferroptosis induced
by erastin, RSL3 and auranofin, suggesting that activation of the RAS/ERK pathway may confer
protection against oxidative stress [104]. However, experiments recently carried out in our laboratories
indicated that RMS cell lines with higher basal RAS/ERK activity are preferentially sensitized towards
ferroptosis (manuscript under preparation). Thus, more detailed studies must be carried out to verify
the relationship between RAS/ERK signaling, oxidative damage and sensitivity to ferroptosis in
RMS. High GSH biosynthesis was reported to be necessary for growth, detoxification, and multidrug
resistance in RMS. For example, increased GSH levels and GSH-S-transferase (GSTs) activity were
observed in high-grade and metastatic STS treated with doxorubicin [105], as well as in ERMS tumors
resistant to doxorubicin, topotecan and vincristine [106]. Moreover, high levels of reduced GSH were
found in the serum of RMS patients [107]. These findings suggest that lowering GSH levels could affect
RMS survival. Recent studies showed that inhibition of the GST isoenzyme, namely GSH transferase
P1-1, with 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX), potentiates cell death in RMS
cells treated with chemotherapeutic agents [102]. In the context of ferroptosis, treatment of RMS with
sorafenib, an inhibitor of system Xc− causing the depletion of endogenous GSH, counteracts cell
proliferation in vitro and xenograft tumor growth in vivo [103]. However, a Phase 2 trial study did not
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show consistent effects of sorafenib in RMS tumor cohorts, nonetheless its combination with irinotecan
or topotecan is being evaluated in children and young adults with refractory solid tumors [108].
Buthionine-sulfoximine (BSO) is another ferroptosis inducer, which inhibits the first reaction of GSH
biosynthesis catalyzed by the γ-glutamylcysteine synthetase (γ-GCSc) [43]. BSO has been shown to
be effective in reducing the tumorigenic potential of two rat RMS cell lines in vitro and in vivo [101].
Interestingly, one of the two cell lines used in this study was more resistant to the BSO treatment.
Biochemical analysis revealed higher levels of γ-glutamyltranspeptidase (γ-GT) [101], a plasma
membrane enzyme of the outer surface responsible for breaking down extracellular GSH to increase
cystine absorption [109], ultimately leading to an increase in intracellular GSH levels. Thus, it could be
argued that the higher γ-GT levels inhibit ferroptosis by increasing GSH levels. Notably, abnormally
high γ-GT enzymatic levels were found in patients with high-grade and metastatic sarcomas [105].
Finally, it has been shown that the treatment of RMS cells with tunicamycin or N-glycosidase is
sufficient to lower GSH levels and cause cell death, suggesting that protein N-glycosylation is required
for GSH biosynthesis [110]. In this regard, the folding and auto-catalytic cleavage of γ-GT has been
shown to be dependent on N-glycosylation [111], suggesting again its potential involvement in
ferroptosis resistance.
4. Conclusions
Recent discoveries shed light on a peculiar iron-dependent non-apoptotic form of cell death,
namely ferroptosis, the execution of which is dependent on the availability of intracellular free iron, the
levels of PUFAs and the levels of enzymes of detoxification from oxidative stress. RMS tumors display
hallmarks of oxidative damage, which could predict the susceptibility of RMS to a number of oxidative
stress inducers. Despite the important role of iron metabolism and iron proteins in cancer, little work
has been done on RMS. Therefore, we discussed the agents involved in ferroptosis activation, believing
that a better understanding of this mechanism in RMS may lead to therapeutic improvements.
Acknowledgments: Funding. The work was supported by Fondazione Cariplo and Regione Lombardia project
“New Opportunities and ways toward European Research Council ERC” 2014-2256 to Maura Poli We would like
to thank Caterina Branca (Arizona State University, Tempe, Arizona, AZ, USA) for text proofreading.
Author Contributions: Alessandro Fanzani and Maura Poli wrote the paper and prepared the figures.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer 2013, 13, 342–355. [CrossRef]
[PubMed]
2. Cazzola, M.; Bergamaschi, G.; Dezza, L.; Arosio, P. Manipulations of cellular iron metabolism for modulating
normal and malignant cell proliferation: Achievements and prospects. Blood 1990, 75, 1903–1919. [PubMed]
3. Ke, J.Y.; Cen, W.J.; Zhou, X.Z.; Li, Y.R.; Kong, W.D.; Jiang, J.W. Iron overload induces apoptosis of murine
preosteoblast cells via ros and inhibition of AKT pathway. Oral Dis. 2017. [CrossRef] [PubMed]
4. Tian, Q.; Wu, S.; Dai, Z.; Yang, J.; Zheng, J.; Zheng, Q.; Liu, Y. Iron overload induced death of osteoblasts
in vitro: Involvement of the mitochondrial apoptotic pathway. Peer J. 2016, 4, e2611. [CrossRef] [PubMed]
5. Li, S.W.; Liu, C.M.; Guo, J.; Marcondes, A.M.; Deeg, J.; Li, X.; Guan, F. Iron overload induced by ferric
ammonium citrate triggers reactive oxygen species-mediated apoptosis via both extrinsic and intrinsic
pathways in human hepatic cells. Hum. Exp. Toxicol. 2016, 35, 598–607. [CrossRef] [PubMed]
6. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.;
Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012,
149, 1060–1072. [CrossRef] [PubMed]
7. Yang, W.S.; Stockwell, B.R. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 2016, 26, 165–176.
[CrossRef] [PubMed]
8. Gaschler, M.M.; Stockwell, B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 2017, 482,
419–425. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1718 8 of 13
9. Cao, J.Y.; Dixon, S.J. Mechanisms of ferroptosis. Cell Mol. Life Sci. 2016, 73, 2195–2209. [CrossRef] [PubMed]
10. Yu, H.; Guo, P.; Xie, X.; Wang, Y.; Chen, G. Ferroptosis, a new form of cell death, and its relationships with
tumourous diseases. J. Cell Mol. Med. 2017, 21, 648–657. [CrossRef] [PubMed]
11. Toyokuni, S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009, 100, 9–16.
[CrossRef] [PubMed]
12. Toyokuni, S.; Ito, F.; Yamashita, K.; Okazaki, Y.; Akatsuka, S. Iron and thiol redox signaling in cancer:
An exquisite balance to escape ferroptosis. Free Radic. Biol. Med. 2017, 108, 610–626. [CrossRef] [PubMed]
13. Ebina, Y.; Okada, S.; Hamazaki, S.; Ogino, F.; Li, J.L.; Midorikawa, O. Nephrotoxicity and renal cell carcinoma
after use of iron- and aluminum-nitrilotriacetate complexes in rats. J. Natl. Cancer Inst. 1986, 76, 107–113.
[PubMed]
14. Van der Kemp, P.A.; Thomas, D.; Barbey, R.; de Oliveira, R.; Boiteux, S. Cloning and expression in
escherichia coli of the OGG1 gene of saccharomyces cerevisiae, which codes for a dna glycosylase that excises
7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine. Proc. Natl. Acad.
Sci. USA 1996, 93, 5197–5202. [CrossRef] [PubMed]
15. Nash, H.M.; Bruner, S.D.; Schärer, O.D.; Kawate, T.; Addona, T.A.; Spooner, E.; Lane, W.S.; Verdine, G.L.
Cloning of a yeast 8-oxoguanine DNA glycosylase reveals the existence of a base-excision DNA-repair
protein superfamily. Curr. Biol. 1996, 6, 968–980. [CrossRef]
16. Aburatani, H.; Hippo, Y.; Ishida, T.; Takashima, R.; Matsuba, C.; Kodama, T.; Takao, M.; Yasui, A.;
Yamamoto, K.; Asano, M. Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA
glycosylase/apurinic, apyrimidinic lyase, a functional mutm homologue. Cancer Res. 1997, 57, 2151–2156.
[PubMed]
17. Kato, J.; Miyanishi, K.; Kobune, M.; Nakamura, T.; Takada, K.; Takimoto, R.; Kawano, Y.; Takahashi, S.;
Takahashi, M.; Sato, Y.; et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development
of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007, 42, 830–836. [CrossRef] [PubMed]
18. Kato, J.; Kobune, M.; Nakamura, T.; Kuroiwa, G.; Takada, K.; Takimoto, R.; Sato, Y.; Fujikawa, K.;
Takahashi, M.; Takayama, T.; et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in
chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001, 61, 8697–8702. [PubMed]
19. Zacharski, L.R.; Chow, B.K.; Howes, P.S.; Shamayeva, G.; Baron, J.A.; Dalman, R.L.; Malenka, D.J.; Ozaki, C.K.;
Lavori, P.W. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: Results
from a randomized trial. J. Natl. Cancer Inst. 2008, 100, 996–1002. [CrossRef] [PubMed]
20. Kasai, H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of
cellular oxidative stress during carcinogenesis. Mutat. Res. 1997, 387, 147–163. [CrossRef]
21. Kondo, S.; Toyokuni, S.; Tanaka, T.; Hiai, H.; Onodera, H.; Kasai, H.; Imamura, M. Overexpression of
the HOGG1 gene and high 8-hydroxy-2′-deoxyguanosine (8-OHDG) lyase activity in human colorectal
carcinoma: Regulation mechanism of the 8-OHDG level in DNA. Clin. Cancer Res. 2000, 6, 1394–1400.
[PubMed]
22. Okamoto, K.; Toyokuni, S.; Kim, W.J.; Ogawa, O.; Kakehi, Y.; Arao, S.; Hiai, H.; Yoshida, O. Overexpression
of human mutt homologue gene messenger RNA in renal-cell carcinoma: Evidence of persistent oxidative
stress in cancer. Int. J. Cancer 1996, 65, 437–441. [CrossRef]
23. Ganz, T.; Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 2012, 1823, 1434–1443. [CrossRef]
[PubMed]
24. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin
regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306,
2090–2093. [CrossRef] [PubMed]
25. Gunshin, H.; Allerson, C.R.; Polycarpou-Schwarz, M.; Rofts, A.; Rogers, J.T.; Kishi, F.; Hentze, M.W.;
Rouault, T.A.; Andrews, N.C.; Hediger, M.A. Iron-dependent regulation of the divalent metal ion transporter.
FEBS Lett. 2001, 509, 309–316. [CrossRef]
26. Arosio, P.; Levi, S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and
oxidative damage. Biochim. Biophys. Acta 2010, 1800, 783–792. [CrossRef] [PubMed]
27. Mancias, J.D.; Wang, X.; Gygi, S.P.; Harper, J.W.; Kimmelman, A.C. Quantitative proteomics identifies
NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014, 509, 105–109. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1718 9 of 13
28. Maffettone, C.; Chen, G.; Drozdov, I.; Ouzounis, C.; Pantopoulos, K. Tumorigenic properties of iron regulatory
protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS ONE 2010, 5, e10163. [CrossRef]
[PubMed]
29. O’Donnell, K.A.; Yu, D.; Zeller, K.I.; Kim, J.W.; Racke, F.; Thomas-Tikhonenko, A.; Dang, C.V. Activation of
transferrin receptor 1 by c-MYC enhances cellular proliferation and tumorigenesis. Mol. Cell Biol. 2006, 26,
2373–2386. [CrossRef] [PubMed]
30. Tacchini, L.; Bianchi, L.; Bernelli-Zazzera, A.; Cairo, G. Transferrin receptor induction by hypoxia.
Hif-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J. Biol. Chem. 1999,
274, 24142–24146. [CrossRef] [PubMed]
31. Habashy, H.O.; Powe, D.G.; Staka, C.M.; Rakha, E.A.; Ball, G.; Green, A.R.; Aleskandarany, M.; Paish, E.C.;
Douglas Macmillan, R.; Nicholson, R.I.; et al. Transferrin receptor (CD71) is a marker of poor prognosis in
breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 2010, 119, 283–293. [CrossRef]
[PubMed]
32. Jeong, D.E.; Song, H.J.; Lim, S.; Lee, S.J.; Lim, J.E.; Nam, D.H.; Joo, K.M.; Jeong, B.C.; Jeon, S.S.; Choi, H.Y.;
et al. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal
cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 2015, 6,
33046–33064. [CrossRef] [PubMed]
33. Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Yamamoto, Y.; Ning, G.; Xian, W.; McKeon, F.; Lynch, M.; Crum, C.P.;
et al. Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene 2017, 36, 4089–4099. [CrossRef]
[PubMed]
34. Torti, S.V.; Torti, F.M. Ironing out cancer. Cancer Res. 2011, 71, 1511–1514. [CrossRef] [PubMed]
35. Wu, K.J.; Polack, A.; Dalla-Favera, R. Coordinated regulation of iron-controlling genes, H-ferritin and Irp2,
by c-MYC. Science 1999, 283, 676–679. [CrossRef] [PubMed]
36. Kakhlon, O.; Gruenbaum, Y.; Cabantchik, Z.I. Repression of ferritin expression modulates cell responsiveness
to H-ras-induced growth. Biochem. Soc. Trans. 2002, 30, 777–780. [CrossRef] [PubMed]
37. Corna, G.; Campana, L.; Pignatti, E.; Castiglioni, A.; Tagliafico, E.; Bosurgi, L.; Campanella, A.; Brunelli, S.;
Manfredi, A.A.; Apostoli, P.; et al. Polarization dictates iron handling by inflammatory and alternatively
activated macrophages. Haematologica 2010, 95, 1814–1822. [CrossRef] [PubMed]
38. Latunde-Dada, G.O. Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim. Biophys. Acta
2017, 1861, 1893–1900. [CrossRef] [PubMed]
39. Doll, S.; Conrad, M. Iron and ferroptosis: A still ill-defined liaison. IUBMB Life 2017, 69, 423–434. [CrossRef]
[PubMed]
40. Xie, Y.; Hou, W.; Song, X.; Yu, Y.; Huang, J.; Sun, X.; Kang, R.; Tang, D. Ferroptosis: Process and function. Cell
Death Differ. 2016, 23, 369–379. [CrossRef] [PubMed]
41. Thomas, C.; Mackey, M.M.; Diaz, A.A.; Cox, D.P. Hydroxyl radical is produced via the fenton reaction
in submitochondrial particles under oxidative stress: Implications for diseases associated with iron
accumulation. Redox Rep. 2009, 14, 102–108. [CrossRef] [PubMed]
42. Skouta, R.; Dixon, S.J.; Wang, J.; Dunn, D.E.; Orman, M.; Shimada, K.; Rosenberg, P.A.; Lo, D.C.;
Weinberg, J.M.; Linkermann, A.; et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse
disease models. J. Am. Chem. Soc. 2014, 136, 4551–4556. [CrossRef] [PubMed]
43. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.;
Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014,
156, 317–331. [CrossRef] [PubMed]
44. Seiler, A.; Schneider, M.; Förster, H.; Roth, S.; Wirth, E.K.; Culmsee, C.; Plesnila, N.; Kremmer, E.; Rådmark, O.;
Wurst, W.; et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase
dependent- and AIF-mediated cell death. Cell Metab. 2008, 8, 237–248. [CrossRef] [PubMed]
45. Ran, Q.; Liang, H.; Gu, M.; Qi, W.; Walter, C.A.; Roberts, L.J.; Herman, B.; Richardson, A.; van Remmen, H.
Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced
apoptosis. J. Biol. Chem. 2004, 279, 55137–55146. [CrossRef] [PubMed]
46. Dolma, S.; Lessnick, S.L.; Hahn, W.C.; Stockwell, B.R. Identification of genotype-selective antitumor agents
using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3, 285–296.
[CrossRef]
Int. J. Mol. Sci. 2017, 18, 1718 10 of 13
47. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent,
nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 2008, 15, 234–245. [CrossRef]
[PubMed]
48. Yagoda, N.; von Rechenberg, M.; Zaganjor, E.; Bauer, A.J.; Yang, W.S.; Fridman, D.J.; Wolpaw, A.J.; Smukste, I.;
Peltier, J.M.; Boniface, J.J.; et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent
anion channels. Nature 2007, 447, 864–868. [CrossRef] [PubMed]
49. Lachaier, E.; Louandre, C.; Godin, C.; Saidak, Z.; Baert, M.; Diouf, M.; Chauffert, B.; Galmiche, A. Sorafenib
induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014,
34, 6417–6422. [PubMed]
50. Louandre, C.; Ezzoukhry, Z.; Godin, C.; Barbare, J.C.; Mazière, J.C.; Chauffert, B.; Galmiche, A.
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 2013,
133, 1732–1742. [CrossRef] [PubMed]
51. Dixon, S.J.; Patel, D.N.; Welsch, M.; Skouta, R.; Lee, E.D.; Hayano, M.; Thomas, A.G.; Gleason, C.E.;
Tatonetti, N.P.; Slusher, B.S.; et al. Pharmacological inhibition of cystine-glutamate exchange induces
endoplasmic reticulum stress and ferroptosis. Elife 2014, 3, e02523. [CrossRef] [PubMed]
52. Sun, X.; Ou, Z.; Xie, M.; Kang, R.; Fan, Y.; Niu, X.; Wang, H.; Cao, L.; Tang, D. HSPB1 as a novel regulator of
ferroptotic cancer cell death. Oncogene 2015, 34, 5617–5625. [CrossRef] [PubMed]
53. Eling, N.; Reuter, L.; Hazin, J.; Hamacher-Brady, A.; Brady, N.R. Identification of artesunate as a specific
activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015, 2, 517–532. [CrossRef] [PubMed]
54. Greenshields, A.L.; Shepherd, T.G.; Hoskin, D.W. Contribution of reactive oxygen species to ovarian cancer
cell growth arrest and killing by the anti-malarial drug artesunate. Mol. Carcinog. 2017, 56, 75–93. [CrossRef]
[PubMed]
55. Doll, S.; Proneth, B.; Tyurina, Y.Y.; Panzilius, E.; Kobayashi, S.; Ingold, I.; Irmler, M.; Beckers, J.; Aichler, M.;
Walch, A.; et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol.
2017, 13, 91–98. [CrossRef] [PubMed]
56. Hayano, M.; Yang, W.S.; Corn, C.K.; Pagano, N.C.; Stockwell, B.R. Loss of cysteinyl-tRNA synthetase
(cars) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation.
Cell Death Differ. 2016, 23, 270–278. [CrossRef] [PubMed]
57. Gao, M.; Monian, P.; Quadri, N.; Ramasamy, R.; Jiang, X. Glutaminolysis and transferrin regulate ferroptosis.
Mol. Cell 2015, 59, 298–308. [CrossRef] [PubMed]
58. Kwon, M.Y.; Park, E.; Lee, S.J.; Chung, S.W. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell
death. Oncotarget 2015, 6, 24393–24403. [CrossRef] [PubMed]
59. Gao, M.; Monian, P.; Pan, Q.; Zhang, W.; Xiang, J.; Jiang, X. Ferroptosis is an autophagic cell death process.
Cell Res. 2016, 26, 1021–1032. [CrossRef] [PubMed]
60. Jiang, L.; Kon, N.; Li, T.; Wang, S.J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated
activity during tumour suppression. Nature 2015, 520, 57–62. [CrossRef] [PubMed]
61. Ou, Y.; Wang, S.J.; Li, D.; Chu, B.; Gu, W. Activation of sat1 engages polyamine metabolism with p53-mediated
ferroptotic responses. Proc. Natl. Acad. Sci. USA 2016, 113, E6806–E6812. [CrossRef] [PubMed]
62. Reed, J.C.; Pellecchia, M. Ironing out cell death mechanisms. Cell 2012, 149, 963–965. [CrossRef] [PubMed]
63. Zhu, S.; Zhang, Q.; Sun, X.; Zeh, H.J.; Lotze, M.T.; Kang, R.; Tang, D. HSPA5 regulates ferroptotic cell death
in cancer cells. Cancer Res. 2017, 77, 2064–2077. [CrossRef] [PubMed]
64. Houessinon, A.; François, C.; Sauzay, C.; Louandre, C.; Mongelard, G.; Godin, C.; Bodeau, S.; Takahashi, S.;
Saidak, Z.; Gutierrez, L.; et al. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular
carcinoma cells exposed to sorafenib. Mol. Cancer 2016, 15, 38. [CrossRef] [PubMed]
65. Sun, X.; Niu, X.; Chen, R.; He, W.; Chen, D.; Kang, R.; Tang, D. Metallothionein-1g facilitates sorafenib
resistance through inhibition of ferroptosis. Hepatology 2016, 64, 488–500. [CrossRef] [PubMed]
66. Warner, G.J.; Berry, M.J.; Moustafa, M.E.; Carlson, B.A.; Hatfield, D.L.; Faust, J.R. Inhibition of selenoprotein
synthesis by selenocysteine tRNA[ser]sec lacking isopentenyladenosine. J. Biol. Chem. 2000, 275, 28110–28119.
[CrossRef] [PubMed]
67. Wang, Y.Q.; Chang, S.Y.; Wu, Q.; Gou, Y.J.; Jia, L.; Cui, Y.M.; Yu, P.; Shi, Z.H.; Wu, W.S.; Gao, G.; et al. The
protective role of mitochondrial ferritin on erastin-induced ferroptosis. Front. Aging Neurosci. 2016, 8, 308.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1718 11 of 13
68. Sun, X.; Ou, Z.; Chen, R.; Niu, X.; Chen, D.; Kang, R.; Tang, D. Activation of the p62-KEAP1-NRF2 pathway
protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 2016, 63, 173–184. [CrossRef]
[PubMed]
69. Fletcher, C.D.M.; Bridge, J.A.; Hogendoorn, P.C.W.; Mertens, F. Who Classification of Tumours of Soft Tissue and
Bone; IARC: Lyon, France, 2013.
70. Linardic, C.M.; Downie, D.L.; Qualman, S.; Bentley, R.C.; Counter, C.M. Genetic modeling of human
rhabdomyosarcoma. Cancer Res. 2005, 65, 4490–4495. [CrossRef] [PubMed]
71. Hettmer, S.; Liu, J.; Miller, C.M.; Lindsay, M.C.; Sparks, C.A.; Guertin, D.A.; Bronson, R.T.; Langenau, D.M.;
Wagers, A.J. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc. Natl.
Acad. Sci. USA 2011, 108, 20002–20007. [CrossRef] [PubMed]
72. Rubin, B.P.; Nishijo, K.; Chen, H.I.; Yi, X.; Schuetze, D.P.; Pal, R.; Prajapati, S.I.; Abraham, J.; Arenkiel, B.R.;
Chen, Q.R.; et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma
and embryonal rhabdomyosarcoma. Cancer Cell 2011, 19, 177–191. [CrossRef] [PubMed]
73. Rodriguez, R.; Rubio, R.; Menendez, P. Modeling sarcomagenesis using multipotent mesenchymal stem cells.
Cell Res. 2012, 22, 62–77. [CrossRef] [PubMed]
74. Parham, D.M.; Alaggio, R.; Coffin, C.M. Myogenic tumors in children and adolescents. Pediatr. Dev. Pathol.
2012, 15, 211–238. [CrossRef] [PubMed]
75. Kashi, V.P.; Hatley, M.E.; Galindo, R.L. Probing for a deeper understanding of rhabdomyosarcoma: Insights
from complementary model systems. Nat. Rev. Cancer 2015, 15, 426–439. [CrossRef] [PubMed]
76. Shern, J.F.; Chen, L.; Chmielecki, J.; Wei, J.S.; Patidar, R.; Rosenberg, M.; Ambrogio, L.; Auclair, D.; Wang, J.;
Song, Y.K.; et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations
affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014, 4,
216–231. [CrossRef] [PubMed]
77. Taylor, J.G.; Cheuk, A.T.; Tsang, P.S.; Chung, J.Y.; Song, Y.K.; Desai, K.; Yu, Y.; Chen, Q.R.; Shah, K.;
Youngblood, V.; et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that
promote metastasis in xenotransplanted models. J. Clin. Investig. 2009, 119, 3395–3407. [PubMed]
78. Stratton, M.R.; Fisher, C.; Gusterson, B.A.; Cooper, C.S. Detection of point mutations in N-ras and K-ras
genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain
reaction. Cancer Res. 1989, 49, 6324–6327. [PubMed]
79. Shukla, N.; Ameur, N.; Yilmaz, I.; Nafa, K.; Lau, C.Y.; Marchetti, A.; Borsu, L.; Barr, F.G.; Ladanyi, M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal
rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res.
2012, 18, 748–757. [CrossRef] [PubMed]
80. Scrable, H.; Cavenee, W.; Ghavimi, F.; Lovell, M.; Morgan, K.; Sapienza, C.C.P. A model for embryonal
rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc. Natl. Acad. Sci. USA 1989, 86,
7480–7484. [CrossRef] [PubMed]
81. Anderson, J.; Gordon, A.; McManus, A.; Shipley, J.; Pritchard-Jones, K. Disruption of imprinted genes
at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999, 1, 340–348. [CrossRef]
[PubMed]
82. Taylor, A.C.; Shu, L.; Danks, M.K.; Poquette, C.A.; Shetty, S.; Thayer, M.J.; Houghton, P.J.; Harris, L.C.
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Med. Pediatr. Oncol. 2000, 35, 96–103. [CrossRef]
83. Skapek, S.X.; Anderson, J.; Barr, F.G.; Bridge, J.A.; Gastier-Foster, J.M.; Parham, D.M.; Rudzinski, E.R.;
Triche, T.; Hawkins, D.S. PAX-FOXO1 fusion status drives unfavorable outcome for children with
rhabdomyosarcoma: A children’s oncology group report. Pediatr. Blood Cancer 2013, 60, 1411–1417. [CrossRef]
[PubMed]
84. Missiaglia, E.; Williamson, D.; Chisholm, J.; Wirapati, P.; Pierron, G.; Petel, F.; Concordet, J.P.; Thway, K.;
Oberlin, O.; Pritchard-Jones, K.; et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular
marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012, 30,
1670–1677. [CrossRef] [PubMed]
85. Mercado, G.E.; Xia, S.J.; Zhang, C.; Ahn, E.H.; Gustafson, D.M.; Laé, M.; Ladanyi, M.; Barr, F.G.
Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal
Int. J. Mol. Sci. 2017, 18, 1718 12 of 13
rhabdomyosarcoma: Focus on mycn as a biologically relevant target. Genes Chromosomes Cancer 2008, 47,
510–520. [CrossRef] [PubMed]
86. Sumegi, J.; Streblow, R.; Frayer, R.W.; Dal Cin, P.; Rosenberg, A.; Meloni-Ehrig, A.; Bridge, J.A. Recurrent
t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to
members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010, 49,
224–236. [PubMed]
87. Agaram, N.P.; Chen, C.L.; Zhang, L.; LaQuaglia, M.P.; Wexler, L.; Antonescu, C.R. Recurrent MYOD1
mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: Evidence for a common
pathogenesis. Genes Chromosomes Cancer 2014, 53, 779–787. [CrossRef] [PubMed]
88. Parham, D.M.; Barr, F.G. Classification of rhabdomyosarcoma and its molecular basis. Adv. Anat. Pathol.
2013, 20, 387–397. [CrossRef] [PubMed]
89. Ognjanovic, S.; Linabery, A.M.; Charbonneau, B.; Ross, J.A.C.P. Trends in childhood rhabdomyosarcoma
incidence and survival in the united states, 1975–2005. Cancer 2009, 115, 4218–4226. [CrossRef] [PubMed]
90. Hettmer, S.; Li, Z.; Billin, A.N.; Barr, F.G.; Cornelison, D.D.; Ehrlich, A.R.; Guttridge, D.C.; Hayes-Jordan, A.;
Helman, L.J.; Houghton, P.J.; et al. Rhabdomyosarcoma: Current challenges and their implications for
developing therapies. Cold Spring Harb. Perspect. Med. 2014, 4, a025650. [CrossRef] [PubMed]
91. Zanola, A.; Rossi, S.; Faggi, F.; Monti, E.; Fanzani, A. Rhabdomyosarcomas: An overview on the experimental
animal models. J. Cell Mol. Med. 2012, 16, 1377–1391. [CrossRef] [PubMed]
92. Shapiro, D.N.; Sublett, J.E.; Li, B.; Downing, J.R.; Naeve, C.W. Fusion of PAX3 to a member of the forkhead
family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 1993, 53, 5108–5112.
[PubMed]
93. Galili, N.; Davis, R.J.; Fredericks, W.J.; Mukhopadhyay, S.; Rauscher, F.J.; Emanuel, B.S.; Rovera, G.; Barr, F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet.
1993, 5, 230–235. [CrossRef] [PubMed]
94. Langenau, D.M.; Keefe, M.D.; Storer, N.Y.; Guyon, J.R.; Kutok, J.L.; Le, X.; Goessling, W.; Neuberg, D.S.;
Kunkel, L.M.; Zon, L.I.C.P. Effects of ras on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007,
21, 1382–1395. [CrossRef] [PubMed]
95. Olson, E.N.; Spizz, G.; Tainsky, M.A. The oncogenic forms of N-ras or H-ras prevent skeletal myoblast
differentiation. Mol. Cell Biol. 1987, 7, 2104–2111. [CrossRef] [PubMed]
96. Aoki, Y.; Niihori, T.; Kawame, H.; Kurosawa, K.; Ohashi, H.; Tanaka, Y.; Filocamo, M.; Kato, K.; Suzuki, Y.;
Kure, S.; et al. Germline mutations in hras proto-oncogene cause costello syndrome. Nat. Genet. 2005, 37,
1038–1040. [CrossRef] [PubMed]
97. Chen, X.; Stewart, E.; Shelat, A.A.; Qu, C.; Bahrami, A.; Hatley, M.; Wu, G.; Bradley, C.; McEvoy, J.; Pappo, A.;
et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013, 24, 710–724. [CrossRef]
[PubMed]
98. Zhang, M.; Linardic, C.M.; Kirsch, D.G. RAS and ROS in rhabdomyosarcoma. Cancer Cell 2013, 24, 689–691.
[CrossRef] [PubMed]
99. Liu, Y.; Li, Y.; Yu, S.; Zhao, G. Recent advances in the development of thioredoxin reductase inhibitors as
anticancer agents. Curr. Drug Targets 2012, 13, 1432–1444. [CrossRef] [PubMed]
100. Bouitbir, J.; Charles, A.L.; Echaniz-Laguna, A.; Kindo, M.; Daussin, F.; Auwerx, J.; Piquard, F.; Geny, B.; Zoll, J.
Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A “mitohormesis” mechanism
involving reactive oxygen species and PGC-1. Eur. Heart J. 2012, 33, 1397–1407. [CrossRef] [PubMed]
101. Castro, B.; Alonso-Varona, A.; del Olmo, M.; Bilbao, P.; Palomares, T. Role of γ-glutamyltranspeptidase
on the response of poorly and moderately differentiated rhabdomyosarcoma cell lines to buthionine
sulfoximine-induced inhibition of glutathione synthesis. Anticancer Drugs 2002, 13, 281–291. [CrossRef]
[PubMed]
102. Pasello, M.; Manara, M.C.; Michelacci, F.; Fanelli, M.; Hattinger, C.M.; Nicoletti, G.; Landuzzi, L.; Lollini, P.L.;
Caccuri, A.; Picci, P.; et al. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas:
A promising therapeutic strategy. Anal. Cell. Pathol. (AMST) 2011, 34, 131–145. [CrossRef] [PubMed]
103. Maruwge, W.; D’Arcy, P.; Folin, A.; Brnjic, S.; Wejde, J.; Davis, A.; Erlandsson, F.; Bergh, J.; Brodin, B. Sorafenib
inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated
signaling. Onco Targets Ther. 2008, 1, 67–78. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1718 13 of 13
104. Schott, C.; Graab, U.; Cuvelier, N.; Hahn, H.; Fulda, S. Oncogenic RAS mutants confer resistance of RMS13
rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. Front. Oncol. 2015, 5, 131.
[CrossRef] [PubMed]
105. Hochwald, S.N.; Rose, D.M.; Brennan, M.F.; Burt, M.E. Elevation of glutathione and related enzyme activities
in high-grade and metastatic extremity soft tissue sarcoma. Ann. Surg. Oncol. 1997, 4, 303–309. [CrossRef]
[PubMed]
106. Seitz, G.; Bonin, M.; Fuchs, J.; Poths, S.; Ruck, P.; Warmann, S.W.; Armeanu-Ebinger, S. Inhibition of
glutathione-s-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
Int. J. Oncol. 2010, 36, 491–500. [CrossRef] [PubMed]
107. Zitka, O.; Skalickova, S.; Gumulec, J.; Masarik, M.; Adam, V.; Hubalek, J.; Trnkova, L.; Kruseova, J.;
Eckschlager, T.; Kizek, R. Redox status expressed as GSH: GSSG ratio as a marker for oxidative stress in
paediatric tumour patients. Oncol. Lett. 2012, 4, 1247–1253. [PubMed]
108. Kim, A.; Widemann, B.C.; Krailo, M.; Jayaprakash, N.; Fox, E.; Weigel, B.; Blaney, S.M. Phase 2 trial of
sorafenib in children and young adults with refractory solid tumors: A report from the children’s oncology
group. Pediatr. Blood Cancer 2015, 62, 1562–1566. [CrossRef] [PubMed]
109. Zhang, H.; Forman, H.J.; Choi, J. γ-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol.
2005, 401, 468–483. [PubMed]
110. Calle, Y.; Palomares, T.; Castro, B.; del Olmo, M.; Alonso-Varona, A. Removal of N-glycans from cell surface
proteins induces apoptosis by reducing intracellular glutathione levels in the rhabdomyosarcoma cell line
s4mh. Biol. Cell 2000, 92, 639–646. [CrossRef]
111. West, M.B.; Wickham, S.; Quinalty, L.M.; Pavlovicz, R.E.; Li, C.; Hanigan, M.H. Autocatalytic cleavage of
human γ-glutamyl transpeptidase is highly dependent on N-glycosylation at asparagine 95. J. Biol. Chem.
2011, 286, 28876–28888. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
